Korro Bio, Inc. KRRO
Korro Bio, Inc. (Nasdaq: KRRO) is a GI/hepatology drug developer. Its lead program, KRRO-121, is in Phase 1 for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). Its next catalyst on record is Novo Nordisk collaboration: Collaboration termination effective (February 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Novo Nordisk collaboration — Collaboration termination effective (February 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KRRO-121 | hyperammonemia in urea cycle disorders and hepatic encephalopathy | oligonucleotide-other | Phase 1 |
| KRRO-111 | alpha-1 antitrypsin deficiency (AATD) | oligonucleotide-other | Pre-clinical |
| KRRO-110 | AATD | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Oct 5, 2026started First cohort of healthy volunteers dosed (single 2 mg/kg dose) in the Phase 1/2 ANCHOR trial of RNA-editing oligonucleotide KRRO-121.
Administered a single dose of 2mg/kg to the first cohort of healthy volunteers
Filing - started Korro started dosing healthy volunteers in the Phase 1/2 ANCHOR trial with KRRO-121.
Dosed the first cohort in ANCHOR (AssessmeNt of Control of Hyperammonemia through Oligonucleotide-based RNA editing), the global Phase 1/2 clinical trial program for KRRO-121 in healthy volunteers and participants with UCD (NCT07773246)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.